Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial

被引:0
|
作者
Yu, Chen [1 ]
Yu, Nan [2 ]
Jiang, Xian [3 ]
Gao, Xinghua [4 ]
Lv, Shichao [5 ]
Wang, Gang [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China
[2] Ningxia Med Univ, Dept Dermatol, Gen Hosp, Yinchuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Dermatol, Chengdu, Peoples R China
[4] China Med Univ, Dept Dermatol, Hosp 1, Shenyang, Peoples R China
[5] 306 Hosp PLA, Strateg Support Force Specialty Med Ctr, Dept Dermatol, Beijing, Peoples R China
关键词
PLAQUE PSORIASIS; GUIDELINES; MANAGEMENT; PYRITHIONE; LIFE; CARE;
D O I
10.1093/ced/llad168
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Controlling relapses of scalp psoriasis is a clinical issue. Zinc pyrithione heals the scalp by normalizing epithelial keratinization or sebum production, or both. Salicylic acid removes scaly hyperkeratotic skin. Supramolecular active zinc antidandruff hair conditioner can relieve the induration of scalp psoriasis lesions. Background Controlling the relapses of scalp psoriasis is a clinical issue. Objectives To evaluate the efficacy and safety of a supramolecular active zinc antidandruff hair conditioner in managing scalp psoriasis (SP). Methods This multicentre randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial enrolled 211 patients with SP between October 2018 and June 2019. The participants were randomized 1 : 1 : 1 to the experimental (supramolecular active zinc antidandruff hair conditioner), placebo (supramolecular hydrogel) or positive control (calcipotriol ointment) group. The primary efficacy endpoint was the disease control rate at the end of the fourth week of treatment, measured using the Investigator's Global Assessment score. Results This study included 70, 70 and 71 participants in the experiment, control and placebo groups, respectively. The disease control rates of SP at the end of week 4 of treatment in the full-analysis set (FAS) were 39%, 25% and 37% in the experimental, placebo and control groups. The margin of superiority between the experimental and placebo groups was > 0 [96% confidence interval (CI) 13.22% (0.43% to & INFIN;)] in the FAS. The experimental group was superior to the placebo group. The noninferiority margin between the experiment and control groups was > -15% [96% CI -1.43% (-14.91% to & INFIN;)] in the FAS. The experimental group was not inferior to the control group. Conclusions Supramolecular active zinc antidandruff hair conditioner was helpful for the treatment of SP, and it has good clinical efficacy in maintaining therapeutic effect and assisting in preventing the recurrence of psoriasis.
引用
收藏
页码:1138 / 1144
页数:7
相关论文
共 50 条
  • [1] A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of MIN-117 in Patients With Major Depressive Disorder
    Davidson, Michael
    Staner, Corinne
    Saoud, Jay
    Noel, Nadine
    Werner, Sandra
    Luthringer, Elisabeth
    Reilly, Joe
    Luthringer, Remy
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S370 - S370
  • [2] A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis
    Elewski, B.
    Pollak, R.
    Ashton, S.
    Rich, P.
    Schlessinger, J.
    Tavakkol, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (02) : 389 - 398
  • [3] Efficacy and safety of Diclofenac sodium plaster in patients with acute pain of the limbs: a randomized, placebo and active-controlled, double-blind, parallel-group trial
    Pabst, H.
    Gruber, G.
    Picciotto, R.
    Barbaro, B.
    Giordan, N.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (07) : 3181 - 3190
  • [4] MIN-117: a randomized, double-blind, parallel-group, placebo- and active-controlled study in patients with major depressive disorder
    Davidson, M.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S785 - S785
  • [5] Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial
    Lai, Pamela M.
    Collaku, Agron
    Reed, Kenneth
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2017, 45 (02) : 647 - 661
  • [6] Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
    Loebel, Antony
    Cucchiaro, Josephine
    Sarma, Kaushik
    Xu, Lei
    Hsu, Chuanchieh
    Kalali, Amir H.
    Pikalov, Andrei
    Potkin, Steven G.
    [J]. SCHIZOPHRENIA RESEARCH, 2013, 145 (1-3) : 101 - 109
  • [7] A randomized, placebo- and active-controlled, parallel-group, multicenter, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis
    Elewski, Boni
    Tavakkol, Amir
    Pollak, Richard
    Ashton, Scott
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB76 - AB76
  • [8] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Sha, Zhongwei
    Hou, Yiping
    Xue, Chunchun
    Li, Ou
    Li, Zhimin
    Wang, Huiru
    Zhang, Wenjing
    Xu, Jian
    [J]. TRIALS, 2020, 21 (01)
  • [9] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Zhongwei Sha
    Yiping Hou
    Chunchun Xue
    Ou Li
    Zhimin Li
    Huiru Wang
    Wenjing Zhang
    Jian Xu
    [J]. Trials, 21
  • [10] Efficacy and safety of vilazodone 20 mg and 40 mg in major depressive disorder: A randomized, double-blind, placebo- and active-controlled trial
    Gommoll, C.
    Mathews, M.
    Chen, D.
    Nunez, R.
    Khan, A.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 96 - 96